Medicina
Cure8 research brief
Why This Matters
For people with UC and CMV colitis, whether to keep or stop immunosuppressive drugs during antiviral treatment may affect how quickly CMV clears from colon tissue and short-term adverse events.
This study suggests continuing immunosuppression was linked to less frequent molecular remission at day 14 and more adverse events, but clinical outcomes were similar at follow-up.
Who Should Pay Attention
Clinicians managing hospitalized UC patients with CMV colitis; gastroenterologists and IBD specialists; adult patients with UC facing CMV colitis; researchers studying IBD infections and treatment strategies.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This prospective cohort from Medicina examined adults hospitalized with ulcerative colitis complicated by biopsy-proven CMV colitis treated with IV ganciclovir. Clinicians chose either temporary discontinuation or continuation of patients’ immunosuppressive therapy. The primary outcome was molecular remission (undetectable tissue CMV DNA) at day 14.
The continuation group had higher residual CMV DNA at day 14 and more adverse events; clinical and endoscopic remission and one-year relapse rates were similar between groups. The authors note corticosteroid exposure only occurred in the continuation group, which could confound results, and they call for larger multicenter studies before changing practice.
Keep In Mind
This is a single-center, non-randomized, exploratory cohort with clinician-selected treatment strategies and small sample size (n=44). Corticosteroid use was unevenly distributed (only in the continuation group), which may confound associations.
Findings are hypothesis-generating and need confirmation in larger randomized or multicenter studies before changing clinical practice.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationMedicina
PublisherMDPI AG
AuthorsZeki Islamoglu, Hasan Yilmaz, Ali Erkan Duman +2 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedAug 9, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Tofacitinib as Rescue Therapy in Steroid-Refractory Acute Severe Ulcerative Colitis: A Retrospective Cohort Study with Observations on Cytomegalovirus Coinfection.
For patients hospitalized with steroid-refractory ASUC, an effective oral rescue option could be useful when standard biologics are unavailable or contraindicated. The study also highlights that high colonic CMV DNA may...
Predictors of ustekinumab intensified dose escalation in inflammatory bowel disease: a real-world (UST-predict) study
People with Crohn’s disease on ustekinumab may be more likely to need intensified dosing if they previously tried biologics or immunomodulators or have had disease longer; this could affect monitoring and planning. For...
Real-World Drug Retention and Safety of Ustekinumab in Patients With Inflammatory Bowel Disease in Qatar: A Retrospective Cohort Study.
This study provides real-world data on how well ustekinumab is kept on treatment and its safety in an Arab IBD population—information that can help patients and clinicians understand longer-term use outside clinical...